In 2005, the Dutch government set out to improve the Netherlands' life sciences landscape by setting up several large consortiums ("top institutes"). It took as its starting point the public health priorities identified in the 2004 WHO report "Priority Medicines for Europe and the World".

By 2006, three top institutes were underway, funded by the government's natural gas reserve fund ("FES"): the Center for Translational Molecular Medicine (CTMM), which focused on diagnostics, the BioMedical Materials program (BMM), which focused on devices, and Top Institute Pharma (TI Pharma), which was tasked with addressing drug research. All three were among the world's first successful public-private partnerships, and all three achieved major and important breakthroughs for the life sciences field.

In its first six years, and through 96 partnerships, TI Pharma delivered:

  • New and enhanced know-how in drug R&D
  • Vastly improved success in priority medicine research
  • A new generation of scientists who thrive in multidisciplinary, collaborative settings
  • A productive, cooperative network across the pharmaceutical landscape

Since 2013, TI Pharma has embarked on a new phase as an independent non-profit that enables international partnership in drug discovery and development.

In 2014, TI Pharma and CTMM announced their merger to address the growing interdependence between medicines and medical technology.

 

 

“TI Pharma's partnerships result in a synergy that really drives the science further than the individual parties could achieve working alone.”

Jan Raaijmakers
Past VP External Scientific Collaborations GSK Europe
Chair TI Pharma Board of Directors

Share this page: